#7: Gilead Sciences (GILD)
Gilead Sciences (GILD) is a biopharmaceutical giant that focuses on rare and hard-to-fight diseases, including HIV/AIDS. These sophisticated medicines are often of the only treatments of their kind, and can be very costly — and very profitable as a result.
How profitable? Well, revenue is set to grow by 12% this year and 31% next year. Profits for fiscal 2013 will finish up about 15%, and are expected to grow by a whopping 60% or better in fiscal 2014 thanks to the hopes of a new hepatitis C drug that recently performed very well in clinical trials. A strong drug pipeline an strong performance of its existing medications will ensure Gilead keeps chugging higher in 2014 … though it might be hard for this stock to double again after the brisk growth of 2013.